Your browser doesn't support javascript.
loading
Decreasing utilization for postoperative radiation therapy in locoregionally advanced medullary thyroid cancer.
Maniakas, Anastasios; Sullivan, Andrew; Hu, Mimi I; Busaidy, Naifa L; Cabanillas, Maria E; Dadu, Ramona; Waguespack, Steven G; Fisher, Sarah B; Graham, Paul H; Gross, Neil D; Grubbs, Elizabeth G; Perrier, Nancy D; Wang, Jennifer R; Gunn, Brandon; Garden, Adam S; Megahed, Romy; Navuluri, Sriram; Li, Xu; Williams, Michelle D; Zafereo, Mark.
Affiliation
  • Maniakas A; Department of Head and Neck Surgery, The University of Texas M. D. Anderson Cancer Center, Houston, Texas, USA.
  • Sullivan A; Department of Head and Neck Surgery, The University of Texas M. D. Anderson Cancer Center, Houston, Texas, USA.
  • Hu MI; Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas M. D. Anderson Cancer Center, Houston, Texas, USA.
  • Busaidy NL; Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas M. D. Anderson Cancer Center, Houston, Texas, USA.
  • Cabanillas ME; Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas M. D. Anderson Cancer Center, Houston, Texas, USA.
  • Dadu R; Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas M. D. Anderson Cancer Center, Houston, Texas, USA.
  • Waguespack SG; Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas M. D. Anderson Cancer Center, Houston, Texas, USA.
  • Fisher SB; Department of Surgical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas, USA.
  • Graham PH; Department of Surgical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas, USA.
  • Gross ND; Department of Head and Neck Surgery, The University of Texas M. D. Anderson Cancer Center, Houston, Texas, USA.
  • Grubbs EG; Department of Surgical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas, USA.
  • Perrier ND; Department of Surgical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas, USA.
  • Wang JR; Department of Head and Neck Surgery, The University of Texas M. D. Anderson Cancer Center, Houston, Texas, USA.
  • Gunn B; Department of Radiation Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas, USA.
  • Garden AS; Department of Radiation Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas, USA.
  • Megahed R; Department of Head and Neck Surgery, The University of Texas M. D. Anderson Cancer Center, Houston, Texas, USA.
  • Navuluri S; Department of Head and Neck Surgery, The University of Texas M. D. Anderson Cancer Center, Houston, Texas, USA.
  • Li X; Department of Head and Neck Surgery, The University of Texas M. D. Anderson Cancer Center, Houston, Texas, USA.
  • Williams MD; Department of Pathology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas, USA.
  • Zafereo M; Department of Head and Neck Surgery, The University of Texas M. D. Anderson Cancer Center, Houston, Texas, USA.
Head Neck ; 46(2): 328-335, 2024 Feb.
Article de En | MEDLINE | ID: mdl-38009416
ABSTRACT

BACKGROUND:

Use of postoperative radiation therapy (PORT) in locoregionally advanced medullary thyroid cancer (MTC) remains controversial. The objective was to evaluate the effect of PORT on locoregional control (LRC) and overall survival (OS).

METHODS:

Retrospective cohort study of 346 MTC patients separated into PORT and no-PORT cohorts. Relative indications for PORT, as well as changes in patterns of treatment, were recorded.

RESULTS:

49/346 (14%) received PORT. PORT was associated with worse OS; adjusted HR = 2.0 (95%CI 1.3-3.3). PORT was not associated with improved LRC, even when adjusting for advanced stage (Stage III p = 0.892; Stage IV p = 0.101). PORT and targeted therapy were not associated with improved OS compared to targeted therapy alone; adjusted HR = 1.2 (95%CI 0.3-4.1).

CONCLUSIONS:

Use of PORT in MTC has decreased and its indications have become more selective, coinciding with the advent of effective targeted therapies. Overall, PORT was not associated with improved LRC or OS.
Sujet(s)
Mots clés

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Tumeurs de la thyroïde / Carcinome neuroendocrine Limites: Humans Langue: En Journal: Head Neck Sujet du journal: NEOPLASIAS Année: 2024 Type de document: Article Pays d'affiliation: États-Unis d'Amérique

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Tumeurs de la thyroïde / Carcinome neuroendocrine Limites: Humans Langue: En Journal: Head Neck Sujet du journal: NEOPLASIAS Année: 2024 Type de document: Article Pays d'affiliation: États-Unis d'Amérique